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Objective: To evaluate the extended follow-up data on efﬁcacy and toxicity of leﬂunomide
therapy in Takayasu arteritis (TA) patients previously enrolled in the original open-label
study  of short-term effects of leﬂunomide in TA.
Methods: An open-label long-term longitudinal study was performed in TA patients who
fulﬁlled the 1990 American College of Rheumatology criteria for TA and had participated in
a  previous study that evaluated short-term efﬁcacy of leﬂunomide in TA. Complete follow-
up  information could be retrieved from 12 out of 15 patients enrolled in the original study.
Disease activity was evaluated by Kerr’s criteria and by the Indian Takayasu Activity Score
2010 (ITAS2010).
Results: The mean follow up time was 43.0 ± 7.6 months and 5 (41.6%) TA patients remained
on  leﬂunomide therapy while 7 (58.3%) TA patients had to change to another therapy due to
failure to prevent relapses in 6 patients and toxicity in one patient. No signiﬁcant differences
were found between patients who remained on leﬂunomide therapy and those who changed
to  another agent regarding age at study entry, time since diagnosis, prednisone daily dose at
study  entry, baseline ITAS2010, mean or maximum ESR and CRP, and cumulative prednisone
dose  at study end. Among TA patients who had changed leﬂunomide to another agent, two
had  an additional clinical relapse and needed to change therapy.
Conclusion: Leﬂunomide led to sustained remission in approximately half of patients at amean  time of 12 months and was well tolerated by TA patients.
© 2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-NDlicense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Leﬂunomida  na  arterite  de  Takayasu  –  Estudo  observacional  de  longo
prazo
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Objetivo: Avaliar os dados de seguimento em longo prazo em relac¸ão à eﬁcácia e toxicidade
do  tratamento com leﬂunomida em pacientes com arterite de Takayasu (AT) previamente
recrutados no estudo aberto original dos efeitos de curto prazo da leﬂunomida na AT.
Métodos: Fez-se um estudo longitudinal aberto de longo prazo com pacientes que
preencheram os critérios para AT da American College of Rheumatology de 1990 e que par-
ticiparam de um estudo anterior que avaliou a eﬁcácia em curto prazo da leﬂunomida na
AT.  Obtiveram-se informac¸ões completas de seguimento de 12 dos 15 pacientes incluídos
no  estudo original. A atividade da doenc¸a foi avaliada pelos critérios de Kerr e pelo Indian
Takayasu Activity Score 2010 (ITAS2010).
Resultados: O tempo médio de seguimento foi de 43,0 ± 7,6 meses. Cinco (41,6%) pacientes
com AT permaneceram em tratamento com leﬂunomida, enquanto sete (58,3%) tiveram de
mudar  para outro tratamento em razão da falha em prevenir recidivas em seis pacientes
e  toxicidade em um paciente. Não foram encontradas diferenc¸as signiﬁcativas entre os
pacientes que continuaram o tratamento com leﬂunomida e aqueles que mudaram para
outro agente em relac¸ão à idade no início do estudo, tempo desde o diagnóstico, dose diária
de  prednisona no início do estudo, ITAS2010 inicial, valor médio ou máximo de VHS e PCR, e
dose  de prednisona cumulativa no ﬁm do estudo. Entre os pacientes com AT que mudaram
de  leﬂunomida para outro agente, dois tiveram nova recidiva clínica e precisaram mudar de
tratamento.
Conclusão: A leﬂunomida levou à remissão sustentada em aproximadamente metade dos
pacientes por um período médio de 12 meses e foi bem tolerada pelos pacientes com AT.
©  2016 Elsevier Editora Ltda. Este e´ um artigo Open Access sob a licenc¸a de CCIntroduction
Takayasu arteritis (TA) is a large vessel vasculitis that is char-
acterized by granulomatous inﬂammation involving the aorta,
its main branches and pulmonary arteries.1 TA affects more
frequently females and the onset of symptoms usually occurs
during the second and third decades of life. Although TA is
described in all ethnic groups, it is more  prevalent in Asians.2
The assessment of disease activity in TA is usually prob-
lematic, because arterial inﬂammation may progress to ﬁxed
vascular injury even in the absence of overt signs and symp-
toms of disease activity.3,4
In patients with active disease, medical therapy of TA
includes high dose prednisone (0.5–1 mg/kg/day) or equiva-
lent as the ﬁrst line. However, relapses occur in up to 50% of
TA patients during corticosteroid tapering and thus immuno-
suppressive agents are usually added to corticosteroid therapy
in order to halt disease progression and to spare corticos-
teroid use.1,5 Conventional immunosuppressive agents used
to treat TA include methotrexate, azathioprine, mycopheno-
late mofetil, leﬂunomide and cyclophosphamide. Recently,
biological agents such as TNF antagonists, tocilizumab and
rituximab were added as treatment options for TA patients
with refractory or severe disease.6
Our group showed a favorable short-term response (mean
follow-up of 9.1 months) to leﬂunomide 20 mg/day in TA
patients with active disease despite therapy with prednisone
and immunosuppressive agents, mainly methotrexate.7 How-
ever, data about long-term efﬁcacy and toxicity of leﬂunomideBY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
in TA are lacking. Therefore, the aims of this study are to
describe the extended follow-up data of efﬁcacy and toxicity of
leﬂunomide therapy in TA patients previously enrolled in the
original open-label study of short-term effects of leﬂunomide
in TA.
Patients  and  methods
This study is an open-label long-term longitudinal study to
evaluate leﬂunomide in TA. TA patients included in this study
fulﬁlled the 1990 American College of Rheumatology criteria
for TA8 and had participated in a previous study that evaluated
short-term efﬁcacy of leﬂunomide in TA.7 From 15 TA patients
enrolled in the original study, complete follow-up information
could be retrieved from 12 patients, since 3 patients were lost
to follow-up.
TA patients were divided into two groups: (A) TA patients
who continued long-term use of leﬂunomide and (B) TA
patients who had to change therapy to another immunosup-
pressive or biological agent. Disease activity was evaluated
by the Kerr’s criteria1 and by the Indian Takayasu Activity
Score 2010 (ITAS2010).9 Acute phase reactants used to evaluate
systemic inﬂammation included the Westergren erythrocyte
sedimentation rate (ESR) and C-reactive protein (CRP). Arte-
rial lesions were assessed by magnetic resonance angiography
(MRA) or by computed tomography angiography (CTA) of the
entire aorta and its main branches. Cumulative prednisone
dose during the follow-up period was calculated for each study
participant. Adverse events attributed to leﬂunomide therapy
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Fig. 1 – Time to replace leﬂunomide to another
immunosuppressive or biological agent. Kaplan–Meier
curve shows two groups of TA patients: group A
(continuous line) comprising patients who continued
leﬂunomide and group B (dashed line) with TA patients
who  changed therapy to other agents. The mean time tor e v b r a s r e u m a t o l
ere recorded. Study’s protocol was approved by the Institu-
ional Ethics Committee and all participants gave informed
onsent.
tatistical  analysis
tatistical analysis was performed with IBM SPSS Statistics for
indows, version 20.0 (Armonk, United States) and graphs
ere built with GraphPad Prism 5.0 software. Categorical
ata are presented as total number (percentage) and contin-
ous data were presented as mean ± standard deviation or
s median and interquartile range as appropriate. Compar-
sons between groups were performed with the Fisher’s exact
est for categorical variables or with the Student’s t test and
ann–Whitney U test for continuous data. A Kaplan–Meier
urve was built to show the time curve of leﬂunomide with-
rawal in TA patients. Accepted signiﬁcance level was 5%
p < 0.05).
esults
he mean age of TA patients at study entry was 34.9 ± 12.5
ears and 11 (91.7%) were females. The mean follow up time
as 43.0 ± 7.6 months and 5 (41.6%) TA patients remained
n leﬂunomide therapy whereas 7 (58.3%) TA patients had to
hange to another therapy due to failure to prevent disease
elapses in 6 patients. Adverse events were observed in two
atients and included diarrhea and gastrointestinal upset, but
nly one of them withdrew leﬂunomide due to these adverse
vents. Leﬂunomide was replaced by inﬂiximab in 4 patients,
y azathioprine in 2 patients and by adalimumab in 1 patient.
nly one out of seven TA patients who changed therapy
eveloped adverse events afterwards, she was on inﬂiximab
nd presented manifested recurrent lower urinary tract infec-
ions. Fig. 1 illustrates the Kaplan–Meier curve for the time
o replace leﬂunomide by other therapies. The mean time
or leﬂunomide withdrawal was 12.8 ± 8.6 months. Groups A
nd B had similar time to prednisone withdrawal [20.8 (range
.8–26.1) months vs. 34.1 (1.7–42.3) months; p = 0.571]. In group
, one patient refused to use prednisone since study entry
nd another could not taper prednisone below 20 mg/day,
hereas in group B two patients could not taper prednisone
s well.
Table 1 – Comparisons between TA patients who remained on 
therapy (group B).
Variables Group A (n =
Age at study entry, years 41.4 ± 12.7 
Disease duration, months 95.0 (73.0–14
Prednisone dose at study entry, mg 11.0 ± 8.9 
ITAS2010 at baseline 6.0 ± 3.5 
Mean ESR during study, mm/h 21.5  ± 15.8 
Mean CRP during study, mg/L 5.6 ± 4.5 
Maximum ESR during study, mm/h 38.8 ± 28.6 
Maximum CRP during study, mg/L 9.4 ± 9.9 
Cumulative prednisone at study end, mg 6,324.8 ± 5,023.
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; ITAS2010, Indreplace leﬂunomide to another agent was 12.8 ± 8.6
months.
No signiﬁcant differences were found between group A
and group B regarding age at study entry, time since diagno-
sis, prednisone daily dose at study entry, baseline ITAS2010,
mean or maximum ESR and CRP, and cumulative prednisone
dose at study end (Table 1). Amongst TA patients who  changed
leﬂunomide to another therapy, two had a clinical relapse and
needed to change therapy with inﬂiximab and adalimumab
to etanercept and inﬂiximab, respectively. New angiographic
lesion was documented in 4 TA patients during the clini-
cal relapse that led to leﬂunomide withdrawal. Nonetheless,
two patients developed new angiographic lesions even after
changing leﬂunomide to another agent, while no new angiog-
raphic lesion could be observed in patients who remained on
leﬂunomide until follow up completion (p = 0.469).Discussion
In this long-term follow up study, we observed that leﬂuno-
mide had to be replaced by another therapy, mostly biological
leﬂunomide (group A) and those who  needed to change
 5) Group B (n = 7) p
30.3 ± 11.1 0.138
4.0) 77.0 (62.0–112.0) 0.465
31.4 ± 19.5 0.056
5.6 ± 3.3 0.864
31.4 ± 21.5 0.407
10.3 ± 10.6 0.379
56.0 ± 31.2 0.354
25.3 ± 15.3 0.072
2 13,366.1 ± 10,492.6 0.247
ian Takayasu’s arteritis activity score.
 o l . 2
r
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agents, in more  than half of TA patients. The main reason
for leﬂunomide withdrawal was failure to prevent disease
relapses, even though a good disease control had been
achieved on the short-term open-label study.7 Moreover,
leﬂunomide was shown to be relatively safe and only one
patient could not tolerate this agent due to diarrhea and
gastrointestinal upset. Limitations of this study include the
low number of patients evaluated and the lack of a control
group.
Indeed, a subgroup of TA patients presented a sustained
response to leﬂunomide with long-term remission leading to
prednisone withdrawal while the development of new arterial
lesions was halted. Although no signiﬁcant differences could
be found between TA patients who  remained on leﬂunomide
and those who needed to change therapy, it is possible that
the latter group presented a more  severe disease course, since
a trend to higher prednisone dose at study entry and higher
maximum CRP levels were observed in these patients from
group B as well as after changing therapy, 2 patients developed
new angiographic lesions despite the use of a TNF antago-
nist.
To date, no randomized controlled trials have evaluated
medical therapy in TA.6 Immunosuppressive and biological
agents were assessed in TA only by open-label studies with
a small number of patients what may be a potential source of
bias. Furthermore, studies that evaluated therapy in TA used
different criteria to assess disease activity and head-to-head
comparisons are not possible.3,10 Recently, the ITAS2010 has
been validated to evaluate disease activity in TA and this out-
come measure yields a numeric score that is useful for patient
monitoring.9 The OMERACT Vasculitis Working Group is devel-
oping a validated set of outcome measures for disease activity
in TA.10 In this study, we  preferred to use Kerr’s criteria and
ITAS2010 to assess disease activity in order to increase sen-
sitivity by using two different outcome measures. Actually, in
some cases we  detected a disease relapse when patients pre-
sented new angiographic lesion and elevated ESR despite the
absence of new complains or changes in physical examina-
tion, in other words ITAS2010 score did not change in some of
the silent relapses of our TA patients.
Regarding immunosuppressive agents, the rate of remis-
sion induction in TA patients for methotrexate, azathioprine
and mycophenolate mofetil was 81.0%, 76.7% and 90.0%,
respectively.11–13 In another study, the use of mycophenolate
mofetil in TA patients with active disease led to a decrease
in median ITAS2010 from 7.0 (range 0.0–19.0) to 1.0 (range
0.0–7.0), p = 0.001, as well as a signiﬁcant reduction of steroid
dose, ESR and CRP values.14 These rates of remission in TA
observed with the use of other immunosuppressive agents are
similar to our ﬁndings with short-term leﬂunomide therapy
for TA (80% of patients in remission at 9.1 months of fol-
low up).7 However, those studies do not report the relapse
rate for the long-term follow up. The follow up period of
our study is slightly higher (3.6 years) than in the above
mentioned studies (i.e. 2.8, 1.0 and 3.0 years, respectively).
The reasons for this apparently lower efﬁcacy of leﬂuno-
mide in keeping sustained remission might be the inclusion
of more  severely ill TA patients or the absence of informa-
tion about relapses after remission was attained in other
studies.11–13
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The use of biological agents in TA has also been evaluated
in open-label studies. Studies that evaluated TNF antagonists
in TA (i.e. inﬂiximab, etanercept and adalimumab) report a
response rate of 89% but a relapse rate of 37% whereas for
tocilizumab the response rate was 100% and a relapse rate of
18%.15 Thus, leﬂunomide induces remission in active TA simi-
larly to TNF antagonists but seems to be inferior to biological
agents in preventing disease relapses in TA.
In conclusion, leﬂunomide leads to sustained remission
and prevents the development of new arterial lesions in
approximately 41% of TA patients at a mean follow up time
of 43 months. Leﬂunomide therapy was well tolerated by TA
patients and the main reason for withdrawal leﬂunomide
therapy is the failure to prevent disease relapses rather than
adverse events.
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